慢性淋巴细胞白血病患者的皮肤癌风险
CLL患者10年皮肤癌绝对风险为13.5%,显著高于对照的6.9%(ARD 6.6个百分点)。CLL患者皮肤癌转移和皮肤癌特异性死亡风险也更高,但绝对风险较低。
要点
- CLL患者10年皮肤癌风险为13.5%,比对照高6.6个百分点。
- 基底细胞癌和鳞状细胞癌是最常见的增加亚型。
- 皮肤癌转移和特异性死亡绝对风险低,但CLL患者仍显著高于对照。
核心结论
- CLL患者皮肤癌总体风险及多数亚型风险显著高于非CLL对照。
- CLL患者皮肤癌特异性转移和死亡风险更高,但绝对风险低。
研究设计与样本
- 丹麦全国性基于人群的匹配队列研究,分析1990年1月至2020年12月登记数据。
- 排除既往皮肤癌或免疫抑制患者,随访从CLL诊断至事件、死亡、移民或研究结束。
主要发现
- CLL患者10年皮肤癌绝对风险13.5%(95%CI 12.7%-14.3%),对照6.9%(95%CI 6.6%-7.2%),ARD 6.6个百分点(95%CI 5.7-7.4,P<.001)。
- 基底细胞癌10年风险CLL组8.6%(95%CI 7.9%-9.2%) vs 对照5.4%(95%CI 5.2%-5.7%),ARD 3.2个百分点(95%CI 2.4-3.8,P<.001)。
- 鳞状细胞癌10年风险CLL组4.7%(95%CI 4.2%-5.2%) vs 对照1.4%(95%CI 1.3%-1.6%),ARD 3.3个百分点(95%CI 2.8-3.8,P<.001)。
- 皮肤癌转移风险CLL组0.7%(95%CI 0.4%-0.9%) vs 对照0.1%(95%CI 0.1%-0.2%),ARD 0.6个百分点(95%CI 0.3-0.7,P<.001)。
- 皮肤癌特异性死亡风险CLL组0.3%(95%CI 0.2%-0.4%) vs 对照0.1%(95%CI 0.1%-0.1%),ARD 0.2个百分点(95%CI 0.1-0.3,P=.004)。
临床怎么用
- 对CLL患者应加强皮肤癌筛查和监测,尤其关注基底细胞癌和鳞状细胞癌。
- CLL患者出现皮肤病变时应警惕皮肤癌转移和特异性死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chronic lymphocytic leukemia (CLL) and its immunosuppressive treatment has been suggested to be associated with increased risk of skin cancer. However, detailed long-term evidence of this association is lacking, including whether an increased skin cancer incidence translates into increased risk of skin cancer-specific metastasis and death in patients with CLL. OBJECTIVE: To assess the overall risk of skin cancer, skin cancer subtypes, and skin cancer-specific metastasis and death among patients with CLL compared with individuals without CLL (controls). DESIGN, SETTING, AND PARTICIPANTS: This nationwide population-based matched cohort study analyzed Danish registry data from January 1990 to December 2020. Follow-up began at CLL diagnosis and continued until an event of interest, death, emigration, or study end. Patients with prior skin cancer or immunosuppression were excluded. Patients with CLL were matched 1:5 with controls based on birth year, sex, geographic region, educational level, income, marital status, and Charlson Comorbidity Index score. Data were analyzed from June to September 2025. MAIN OUTCOMES AND MEASURES: Absolute risks and risk differences for overall skin cancer, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma, melanoma, cutaneous lymphoma, and skin cancer-specific metastasis and death. All risks were estimated using multivariable cause-specific Cox proportional hazards regression models with death from other causes as a competing risk. RESULTS: Among the 8352 patients with CLL included in the study (median age, 70.7 years [IQR, 62.2-78.3 years]; 4902 [58.7%] male), the absolute 10-year risk of skin cancer was 13.5% (95% CI, 12.7%-14.3%) compared with 6.9% (95% CI, 6.6%-7.2%) among 41 760 controls (median age, 70.7 years [IQR, 62.2-78.2 years]; 24 510 [58.7%] male), resulting in an absolute risk difference (ARD) of 6.6 percentage points (pp) (95% CI, 5.7-7.4 pp; P < .001). Patients with CLL had an increased risk of most skin cancer subtypes compared with controls, with the most common being basal cell carcinoma (8.6% [95% CI, 7.9%-9.2%] vs 5.4% [95% CI, 5.2%-5.7%]; ARD, 3.2 pp [95% CI, 2.4-3.8 pp]; P < .001) and squamous cell carcinoma (4.7% [95% CI, 4.2%-5.2%] vs 1.4% [95% CI, 1.3%-1.6%]; ARD, 3.3 pp [95% CI, 2.8-3.8 pp]; P < .001). Patients with CLL, compared with controls, had a higher risk of both skin cancer metastasis (0.7% [95% CI, 0.4%-0.9%] vs 0.1% [95% CI, 0.1%-0.2%]; ARD, 0.6 pp [95% CI, 0.3-0.7 pp]; P < .001) and skin cancer-specific death (0.3% [95% CI, 0.2%-0.4%] vs 0.1% [95% CI, 0.1%-0.1%]; ARD, 0.2 pp [95% CI, 0.1-0.3 pp]; P = .004). All-cause mortality among patients with CLL was 56.3% (95% CI, 55.3%-57.2%) compared with 39.3% (95% CI, 38.8%-39.8%) among controls (ARD, 17.0 pp; 95% CI, 16.0-18.0 pp; P < .001). CONCLUSIONS AND RELEVANCE: This cohort study found that patients with CLL had an increased risk of developing skin cancer, mainly basal cell carcinoma and squamous cell carcinoma. Skin cancer-specific metastasis and death were also more frequent among patients with CLL, although the absolute risk remained low given markedly higher all-cause mortality.
引用
- Drejøe AMB, Hemmingsen MN, Wulff IK, et al. Risk of Skin Cancer Among Patients With Chronic Lymphocytic Leukemia. JAMA Dermatol. 2026. PMID: 41920537. doi:10.1001/jamadermatol.2026.0355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。